[1]尹湘君 阮家钊 柴毅 季旭明.非小细胞肺癌化疗后温下方加减干预临床疗效研究[J].陕西中医药大学学报,2021,44(02):075-79.[doi:10.13424/j.cnki.jsctcm.2021.02.015]
 YIN Xiang - jun,RUAN Jia - zhao,CHAI Yi,et al.Study on The Clinical Effects of Modified Warming Purging Prescription intervention after Chemotherapy for Non – small Cell Lung Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,44(02):075-79.[doi:10.13424/j.cnki.jsctcm.2021.02.015]
点击复制

非小细胞肺癌化疗后温下方加减干预临床疗效研究()
分享到:

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
44
期数:
2021年02期
页码:
075-79
栏目:
出版日期:
2021-03-26

文章信息/Info

Title:
Study on The Clinical Effects of Modified Warming Purging Prescription intervention after Chemotherapy for Non – small Cell Lung Cancer
文章编号:
2096-1340(2021)02-0075-05
作者:
尹湘君 阮家钊 柴毅 季旭明
浙江中医药大学,浙江 杭州 310053
Author(s):
YIN Xiang - jun RUAN Jia - zhao CHAI Yi JI Xu – ming
School of basic medicine, Zhejiang University of traditional Chinese medicine, Hangzhou 310053,China
关键词:
非小细胞肺癌化疗温下方临床疗效阳虚寒凝
Keywords:
Non - small cell lung cancer Chemotherapy Warming purging prescription Clinical efficacy Yang de-ficiency and cold coagulation
分类号:
R734
DOI:
10.13424/j.cnki.jsctcm.2021.02.015
文献标志码:
A
摘要:
目的 观察非小细胞肺癌(non - small cell lung cancer, NSCLC)患者化疗后运用温下方加减的治疗效果? 方法 纳入 NSCLC 化疗后患者32 例,核心病机均为阳气不足,寒凝瘀滞,运用温下方加减治疗并进行疗效评价,评价主要指标为:瘤灶近期疗效,临床症状评分,肺癌治疗功能评价量表(FACT - L)评分,卡氏(KPS)评分。结果 治疗前后患者瘤灶近期疗效未见显著差异(P > 0. 05);温下方加减干预后患者临床症状总评分较前明显降低(P <0. 01);肺癌治疗功能评价量表中,生理状况、功能状况、肺癌特异模块评分及总分较治疗前显著增加(P <0. 05);KPS 评分显示治疗后评分较治疗前显著升高(P <0. 01)。 结论 温下方加减治疗 NSCLC 化疗后患者,可有效改善患者临床症状,提高患者生活质量。
Abstract:
Objective To observe the therapeutic effect of modified warming purging prescription after chemotherapy in patients with non - small cell lung cancer (NSCLC). Methods 32 patients with NSCLC after chemotherapy were in-cluded in this study. The core pathogenesis was deficiency of Yang Qi, cold coagulation and blood stasis. The main out-come measures were short - term efficacy, clinical symptom score, FACT - L score and KPS score. Results There was no significant difference in the short - term curative effect of tumor focus before and after treatment (P > 0. 05); the total score of clinical symptoms was significantly lower than before (P < 0. 01); in the lung cancer treatment function evalua-tion scale, the physiological status, functional status, lung cancer specific module score and total score were significantly increased than before treatment (P <0. 05); KPS score showed that the score after treatment was significantly higher than before treatment 01). Conclusion Modified warming purging prescription can effectively improve the clinical symptoms and quality of life of patients with NSCLC after chemotherapy.Objective To observe the therapeutic effect of modified warming purging prescription after chemotherapy in patients with non - small cell lung cancer (NSCLC). Methods 32 patients with NSCLC after chemotherapy were in-cluded in this study. The core pathogenesis was deficiency of Yang Qi, cold coagulation and blood stasis. The main out-come measures were short - term efficacy, clinical symptom score, FACT - L score and KPS score. Results There was no significant difference in the short - term curative effect of tumor focus before and after treatment (P > 0. 05); the total score of clinical symptoms was significantly lower than before (P < 0. 01); in the lung cancer treatment function evalua-tion scale, the physiological status, functional status, lung cancer specific module score and total score were significantly increased than before treatment (P <0. 05); KPS score showed that the score after treatment was significantly higher than before treatment 01). Conclusion Modified warming purging prescription can effectively improve the clinical symptoms and quality of life of patients with NSCLC after chemotherapy.

参考文献/References:

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7 -30.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA Cancer J Clin, 2018, 68(6): 394 -424.
[3] Zheng J, Wu M, Wang H, et al. Network pharmacology to unveil the biological basis of health – strengthening herbal medicine in cancer treatment [J]. Cancers (Ba-sel), 2018, 10(11): E461.
[4] 李玉潇,张孝刚,胡帅航,等. 中医药维持治疗晚期非小细胞肺癌的研究现状及展望 [J]. 中医药信息,2020, 37(4): 126 -129.
[5] 宋立家,季旭明,王海瑞,等. 温阳法治疗肿瘤研究进展 [J]. 中医药信息, 2015, 32(1): 118 -21.
[6] Wang MR, Chen RJ, Zhao F, et al. Effect of Wenxia Changfu formula combined with cisplatin reversing non -small cell lung cancer cell adhesion - mediated drug re-sistance [J]. Front Pharmacol, 2020, 11(500):137.
[7] Zhang Y, Wu Z, Yu H, et al. Chinese herbal medicine Wenxia Changfu formula reverses cell adhesion – mediated drug resistance via the integrin β1 - PI3K - AKT pathway in lung cancer [J]. J Cancer, 2019, 10(2): 293 -304.
[8] Ji XM, Wu ZC, Liu GW, et al. Wenxia Changfu formula induces apoptosis of lung adenocarcinoma in a transplan-ted tumor model of drug - resistance nude mice[J]. Chin J Integr Med, 2016, 22(10): 752 -758.
[9] 中国抗癌协会. 新编常见恶性肿瘤诊治规范(合订本)[M]. 北京: 中国协和医科大学出版社, 1999: 773-781.
[10] Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system [J]. Chest, 2009, 136(1): 260-271.
[11] 国家食品药品监督管理局. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社, 2002:219 -221.
[12] 林洪生. 恶性肿瘤中医诊疗指南 [M]. 北京:人民卫生出版社, 2014: 242 -267.
[13] 朱文锋. 中医诊断学 [M]. 北京:中国中医药出版社, 2002.
[14] Eisenhauer E A, Therasse P, Bogaerts J, et al. New re-sponse evaluation criteria in solid tumours: revised RE-CIST guideline (version 1. 1) [J]. Eur J Cancer, 2009,45(2): 228 -247.
[15] Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer:Testing the lung cancer symptom scale(LCSS) [J]. Eur J Cancer,1993, 29A: S51 - S58.
[16] 国家药品监督管理局. 关于发布证候类中药新药临床研究技术指导原则的通告 [EB/ OL]. (2018 - 11 -01) [2020 - 10 - 15]. https:/ / www. nmpa. gov. cn/yaopin/ ypggtg/ ypqtgg/20181106155701473. html
[17] 李红莲. 补肺消积汤辅助治疗非小细胞肺癌的疗效及其对生存质量的影响[J]. 慢性病学杂志, 2020, 21(1): 130 -132.
[18] 孙燕,石远凯. 临床肿瘤内科手 [M]. 北京:人民卫生出版社, 2007: 142 -145.
[19] 王成弟,陈勃江,宋璐佳,等. 23228 例肺癌患者临床流行病学及病理特征趋势分析 [J]. 华西医学, 2020,35(7): 813 -820.
[20] Allemani C, Matsuda T, Di Carlo V, et al. Global sur-veillance of trends in cancer survival 2000 - 14 (CON-CORD -3): analysis of individual records for 37? 513?025 patients diagnosed with one of 18 cancers from 322population - based registries in 71 countries [J]. Lancet,2018, 391(10125): 1023 -1075.
[21] 杨建芬,沈永奇. 肿瘤化疗相关性恶心呕吐的防治进展 [J]. 中国当代医药, 2019, 26(15): 32 -35.
[22] Li L, Wang T, Hu M, et al. Metformin overcomes ac-quired resistance to EGFR TKIs in EGFR - mutant lung cancer via AMPK/ ERK/ NF - κB signaling pathway [J].Front Oncol, 2020,(10): 1605.
[23] 龚自坤,郑秋惠,梅凯雁. 肿瘤化疗后恶心呕吐的中医治疗研究进展 [J]. 亚太传统医药, 2020, 16(9):200 -205.
[24] 王海瑞,季旭明,宋立家. 基于中医传承辅助平台治疗中晚期肺癌方剂组方规律 [J]. 中国老年学杂志,2015, 35(13): 3614 -3617.
[25] 周莹,张韧,黄意勉,等. 基于网络药理学和分子生物学探讨温下方治疗肺癌的作用机制 [J]. 广州中医药大学学报, 2020, 37(10): 1956 -1963.

相似文献/References:

[1]关茜1 焦俊?1 叶子豪1 王克穷2.益脾扶正方联合化疗治疗中晚期食管癌 21 例[J].陕西中医药大学学报,2019,(01):150.[doi:10.13424/j.cnki.jsctcm.2019.01.045]
 Guan Qian Jiao Junzhe Ye Zihao Wang Keqiong.Clinical Analysis of Yipi Fuzheng Recipe combined with Chemotherapy in the Treatment of Advanced Esophageal Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2019,(02):150.[doi:10.13424/j.cnki.jsctcm.2019.01.045]
[2]刘追星 杨洋陈光伟 方瑜.扶正抗癌方联合化疗对中晚期非小细胞肺癌患者外周血 CD4+?CD8+ 细胞影响的临床研究[J].陕西中医药大学学报,2020,(5):076.[doi:10.13424/j.cnki.jsctcm.2020.05.019]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(81774198)
通讯作者:季旭明,教授 E - mail: jixuming724@163. Com
更新日期/Last Update: 2021-03-29